---
title: "Cue Biopharma Raises ~$50 Million in Private Placement With Cormorant, Columbia Threadneedle"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292360208.md"
description: "Cue Biopharma announced a private placement raising approximately $50 million from investors including Cormorant Asset Management and Columbia Threadneedle Investments. The transaction, closing July 13, 2026, involves issuing common shares and pre-funded warrants at roughly $33.21 per share. Funds will support clinical development and general corporate purposes. Concurrently, Cue granted resale registration rights to investors, committing to file a resale statement within 30 days."
datetime: "2026-07-10T21:33:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292360208.md)
  - [en](https://longbridge.com/en/news/292360208.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292360208.md)
---

# Cue Biopharma Raises ~$50 Million in Private Placement With Cormorant, Columbia Threadneedle

Cue Biopharma announced a private placement expected to close on July 13, 2026, raising approximately $50.0 million to support clinical development and general corporate purposes. Under a Securities Purchase Agreement, investors will acquire 1,418,071 common shares at $33.21 per share and pre-funded warrants for 87,500 shares at $33.209 per warrant, each with a $0.001 exercise price and cashless exercise. Concurrently, a Registration Rights Agreement commits the company to file a resale registration statement within 30 days of closing and maintain effectiveness until all registrable securities are sold. The financing includes investor ownership limits and customary conditions and indemnities.

**Agreement 1: Cue Biopharma Raises ~$50 Million in Private Placement With Cormorant, Columbia Threadneedle**

-   **Agreement type**: Securities Purchase Agreement for private placement of equity
-   **Counterparty**: Accredited investors including Cormorant Asset Management and Columbia Threadneedle Investments
-   **Signed / Effective**: Jul 09 2026 / Jul 13 2026
-   **Reason**: Raise capital for clinical development and corporate needs

**Agreement 2: Cue Biopharma Grants Investors Resale Registration Rights Following $50 Million Financing**

-   **Agreement type**: Registration Rights Agreement covering resale of securities
-   **Counterparty**: Investors from the private placement
-   **Signed / Effective**: Jul 09 2026 / Jul 13 2026
-   **Duration / Termination**: Until all registrable securities are sold
-   **Reason**: Provide resale liquidity to investors

Original SEC Filing: Cue Biopharma, Inc. \[ CUE \] - 8-K - Jul. 10, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CUE.US](https://longbridge.com/en/quote/CUE.US.md)

## Related News & Research

- [Cue Biopharma Chief Executive Officer Sold Shares Worth Over $1.6M](https://longbridge.com/en/news/295986047.md)
- [Rocket Companies director Sarah Watterson files Form 3 initial beneficial ownership statement](https://longbridge.com/en/news/296141298.md)
- [Bausch + Lomb files Form 3 disclosing director Thomas Appio stake of 27,583 shares](https://longbridge.com/en/news/295977890.md)
- [Apollo Global Management files Form 3 initial beneficial ownership statement for LDB 2025 LLC](https://longbridge.com/en/news/295974245.md)
- [Freedom Holding files Form 3 as Chief Logistics Officer Marat Shotbayev reports 252 shares stake](https://longbridge.com/en/news/295924722.md)